We are live on ! Find out more
WHWK

Whitehawk Therapeutics

24 hedge funds and large institutions have $18.3M invested in Whitehawk Therapeutics in 2018 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 4

20% more funds holding

Funds holding: 2024 (+4)

0% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 3

0.1% less ownership

Funds ownership: 1.87%1.77% (-0.1%)

48% less capital invested

Capital invested by funds: $35.2M → $18.3M (-$16.9M)

Holders
24
Holders Change
+4
Holders Change %
+20%
% of All Funds
0.53%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
8
Increased
3
Reduced
3
Closed
4
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Goldman Sachs
26
Goldman Sachs
New York
-$335K -7,230 Closed
SIM
27
Spark Investment Management
New York
-$31K -687 Closed
CIBC Private Wealth Group
28
CIBC Private Wealth Group
Georgia
-$31K -667 Closed

WHWK Hedge Fund Activity: Q4 2018 in Review

24 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Whitehawk Therapeutics (WHWK) for Q4 2018, worth a combined $18.3M — down 48% from $35.2M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new WHWK positions and 4 closed out — a net gain of 4 holders — while 3 added to existing stakes and 3 trimmed.

The largest buyer was Citigroup, opening a new position worth an estimated $514K. The largest seller was Fidelity Investments, exiting entirely with an estimated $1.75M sold.

  • 24 institutional investors held Whitehawk Therapeutics (WHWK) as of Q4 2018, up from 20 in Q3 2018.
  • Funds reported $18.3M of Whitehawk Therapeutics stock for Q4 2018, down 48% quarter-over-quarter.
  • 8 funds opened new Whitehawk Therapeutics positions in Q4 2018 and 4 closed out, a net change of +4 holders.
  • The largest Whitehawk Therapeutics buyer in Q4 2018 was Citigroup, an estimated $514K added.
  • The largest Whitehawk Therapeutics seller in Q4 2018 was Fidelity Investments, an estimated $1.75M sold.

Based on aggregated 13F filings for Q4 2018.